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ABSTRACT
Uterine endometrial stromal sarcomas including true low-grade endometrial stromal sarcoma (LG-ESS) and high-grade 
(HG-ESS) or undifferentiated endometrial sarcoma (UES) constitute a group of rare, aggressive malignancies. Most LG-ESSs 
express steroid receptors. Surgery is the principal primary therapy for endometrial stromal sarcomas and should be 
considered in all cases. These malignancies are relatively radio- and chemoresistant. Chemotherapy is used in recurrent 
and advanced HG-ESS and UES. Currently, the combination of gemcitabine and docetaxel is considered the most effec-
tive regimen, but at the expense of substantial toxicity. In steroid receptor positive advanced LG-ESS hormonal therapy, 
mainly with progestins, allows in some patients for a long-term survival. Aromatase inhibitors seem to be equally effective 
as first- and subsequent-line of treatment, and are well tolerated. The role of molecular-targeted therapies in endometrial 
stromal sarcomas remains to be established.
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INTRODUCTION
Endometrial stromal sarcomas are rare tumors of pure 
mesenchymal origin, comprising approximately 0.2% of all 
uterine malignancies and 10–25% of all uterine sarcomas [1]. 
According to the World Health Organisation (WHO) classifi-
cation from 2014, there is a distinction between true endo-
metrial stromal sarcoma (ESS), also known as a low-grade 
endometrial stromal sarcoma (LG-ESS), and high-grade 
(HG-ESS) or undifferentiated endometrial or stromal sar-
coma (UES). These subtypes are defined based on clinical 
and pathologic features.
The most sensitive marker for ESS is a CD10-antigen and 
a cytogenetic hallmark of this tumor is a t(7;17)(p15;q21) 
(JAZF1-JJAZ1) rearrangement [1–3]. ESSs are relatively more 
common than non-LG-ESSs, with most cases occurring be-
fore menopause. ESS is generally a slow-growing malig-
nancy with an indolent clinical course. In most women ESS 
is diagnosed in an early stage, and 65–86% of reported 
cases are confined to the uterus. The reported 5-year overall 
survival (OS) rates are in the range of 80–100%, but 40–50% 
of patients even after 20 years will develop relapse, which 
is typically located in the pelvis, abdomen or lungs [1, 4]. 
In contrast, HG-ESS, usually characterized by the t(10;17)
(q22;p13) translocation (YWHAE-FAM22 rearrangements), 
and UES which exhibits no specific translocation pattern, 
have typical for sarcomas, aggressive clinical behavior [5, 6]. 
Of note, molecular diagnostics is helpful but not essential for 
the diagnosis of non-LG-ESS. Poor prognosis, similar to that 
in leiomyosarcoma (LMS), is a result of its high recurrence 
propensity, both locally and at distant sites [5]. Treatment re-
sults of non-LG-ESS are relatively poor, with merely 25–55% 
five year survival. Cases of extrauterine endometrial stromal 
sarcoma (typically developing from endometriosis) and af-
fecting young pregnant women have been reported [7, 8]. 
Surgery consisting of total hysterectomy and bilateral 
salpingo-ophorectomy is the principal therapy of early en-
dometrial stromal sarcomas, whereas the role of elective 
lymphadenectomy is not well established. Ovary-sparing 
surgery in young women with early ESS is a matter of debate, 
as this procedure is associated with relatively high risk of 
local recurrence [9]. The role of postoperative radiotherapy 
and hormonal therapy in ESS is also not well established 
[10–12]. Cytoreductive surgery should also be considered 
in all metastatic and recurrent cases. This management 
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is an independent predictor of better survival after ESS 
recurrence [13]. 
Due to the rarity of endometrial stromal sarcomas, the 
current knowledge is mainly based on case reports. We 
present here contemporary systemic treatment options for 
advanced ESS and non-LG-ESS.   
CHEMOTHERAPY
Chemotherapy, in addition to palliative radiotherapy 
and surgery has been used in recurrent and advanced 
non-LG-ESS, and in hormone-unresponsive ESS cases. There 
has been only one prospective phase II study investigating 
the role of first-line chemotherapy in patients with endo-
metrial stromal sarcomas, conducted by Gynecologic On-
cology Group (GOG) [14]. This study included 31 patients 
with primary advanced or recurrent disease and used if-
osfamide at a dose of 1.5 g/m2 given on days 1–5, every 
3 weeks. Overall 33% of patients responded to treatment, 
14% with complete and 19% with partial remission, respec-
tively. The median progression-free survival in the entire 
group was 3 months. 
Chemotherapy includes compounds used in other 
soft-tissue sarcomas, such as anthracyclines, dacarbazine, 
vinorelbine, gemcitabine, docetaxel and temozolomide. 
This cytotoxis are administered alone or in doublets, eg. 
docetaxel/gemcitabine, doxorubicin/ifosfamide, doxoru-
bicin/dacarbazine, gemcitabine/dacarbazine or gemcit-
abine/vinorelbine. The combination of gemcitabine and 
docetaxel as both the first- and second-line therapy in LMS 
was investigated in two phase II trials conducted by GOG 
[15, 16]. This regimen included 900 mg/m2 of gemcitabine 
on days 1 and 8 plus docetaxel 100 mg/m2 on day 8, given 
every 3 weeks with a granulocyte colony-stimulating factor. 
The response rate of 36% reported in the first-line setting 
compares favorably to 20–30% response rates observed 
with single-agent doxorubicin (typically at doses of about 
60 mg/m2 every 3 weeks). A case of long-term complete 
remission of ESS following 12 cycles of gemcitabine plus 
docetaxel was reported [17]. Toxicities accompanying this 
regimen include myelosuppression, fatigue and fluid reten-
tion but, as opposed to anthracycline-based regimens, may 
be continued for a longer period of time without limiting 
cardiac toxicity. More recently, a partial regression was re-
ported in one out of three patients with non-LG-ESS treated 
with trabectedin as a salvage treatment [18]. No effect was 
reported in a non-LG-ESS case treated with paclitaxel and 
carboplatin [19].  
ENDOCRINE THERAPY
Almost 80% of ESS express estrogen alpha (ER) and 
progesterone receptors (PgR) [1]. The PgR A is the domi-
nant isoform in primary ESS, whereas, recurrent tumors are 
characterized by PgR B expression. Additionally, most ESS 
cases show the intratumoral immunohistochemical expres-
sion of aromatase and gonadotropin releasing hormone 
(GnRH) receptor.
In steroid receptor positive advanced ESSs, considered 
to be radio- and chemotherapy resistant, hormonal ther-
apy constitutes a standard management which improve 
long-term survival. This therapy induces a proportion of 
durable responses or disease stabilizations. There are no 
specific guidelines specifying particular endocrine therapies 
and their sequence. Several case reports and small series 
demonstrated long-term benefit of progestin treatments in-
cluding megestrol acetate or medroxyprogesterone acetate 
(MPA) used at doses of 200 mg up to even 1000 mg/day in 
continuous or intermittent schedules [20 –22]. Progestins are 
used as the first-line treatment, after prior chemotherapy 
and as an adjunct to complete resection of metastatic le-
sions. Apart from weight gain, side-effects of long-term 
high-dose progestin therapy include increased risk of severe 
depression and thromboembolic complications [1]. Hence, 
currently the third generation aromatase inhibitors (AIs) 
and GnRH analogues have become alternative endocrine 
treatments for ESS.
Data on the efficacy of AIs for ESS are scarce, with most 
published studies being case reports [23–30]. There is a re-
port of complete responses lasting for more than 7 and 
14 years in two patients with lung metastases treated with 
aminoglutethimide (500 mg bid) [28]. Another study re-
ported two year disease stabilization in ESS with sex-cord 
compound, treated with anastrozole and megestrol acetate 
[25]. Letrozole, another most frequently reported non-ste-
roid AI, was used both in the first-line therapy and after 
failure on progestins and tamoxifen. Responses were usually 
partial, however complete responses were also reported. 
These include a patient with lung metastases who achieved 
a complete response lasting for more than 27 months after 
sequential therapy with letrozole (for 8 months) and anas-
trozole [23]. In a series of five patients treated with letrozole, 
durable partial response was obtained in all three cases 
administered AI as primary treatment and in one treated 
with MPA [26]. In another series of five patients treated 
with letrozole for unresectable peritoneal recurrent ESS two 
patients achieved complete responses lasting for 96 and 
87 months [30]. These tumors were positive for ER, PgR and 
CD10, and negative for CD117. Good tolerance of letrozole 
was reported in all studies. 
The efficacy of GnRH analogues and their role in com-
plete estrogen deprivation remains to be established [31, 
32]. The same is true for a PgR modulator mifepristone [33]. 
Notably, the selective ER-modulator tamoxifen is contraindi-
cated in the treatment of ESS as it has an agonistic activity 
on endometrial stromal cells. 
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TARGETED THERAPIES
The immunohistochemical expression of potential ther-
apeutic targets: c-Kit, c-abl, plateled-derived growth factor 
receptor (PDGFR) and epidermal growth factor receptor 
(EGFR) in endometrial stromal tumors varied among studies 
based mostly on single cases or small series. In the largest 
series investigating  potential targets for tyrosine kinase 
inhibitors (TKI) immunohistochemical or molecular altera-
tions of c-Kit, PDGFRα and EGFR were demonstrated in 2%, 
34.6% and 11.5% of ESSs, and in 7.7%, 38.5% and 7.7% of 
non-LG-EESs, respectively [34]. This study included 52 ESSs 
and 13 UESs subclassified using the WHO classification. 
There are some anecdotal reports of response to c-Kit 
inhibitor imatinib in disseminated non-LG-ESS and ESS, 
mainly after chemotherapy failure [35–38]. This includes 
a case of 8-month regression of c-Kit negative ESS tumor, 
with strong expression of PDGFR α and β [38].   
CONCLUSIONS
Due to rarity of endometrial stromal sarcomas there 
have been no randomized controlled trials investigating 
the role of systemic therapies in these tumors in advanced 
disease setting. Palliative chemotherapy has limited role 
in non-LG-ESS. Considering both activity and toxicity, 
doxorubicin or ifosfamide even as monotherapy seems to 
be the first-line choice in soft tissue sarcomas including 
non-LG-ESS. Gemcitabine/docetaxel combination provides 
somewhat higher response rates but at the cost of increased 
toxicity.  Hormonal therapy with progestins, mainly MPA, is 
an effective long-term palliative management for steroid 
receptor positive ESS. AIs, particularly letrozole, seem to be 
also effective as first- and later-line endocrine treatment, and 
are well tolerated. The role of molecular-targeted therapies 
in endometrial stromal sarcomas remains to be established.
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